US EditionViroCell and UCL launch trial to treat childhood leukaemia relapse - Pharmafile
Summary by pharmafile.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
ViroCell and UCL launch trial to treat childhood leukaemia relapse - Pharmafile
ViroCell Biologics has manufactured a GMP-grade lentiviral vector for a University College London (UCL) clinical trial aimed at tackling relapse in paediatric acute lymphoblastic leukaemia (ALL), a common childhood cancer. Led by professor Persis Amrolia, a pioneer in CAR T-cell therapy at UCL and Great Ormond Street Hospital (GOSH), the trial intends to improve outcomes […] The post ViroCell and UCL launch trial to treat childhood leukaemia rel…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
